Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
3.010
-0.030 (-0.99%)
Oct 30, 2025, 4:00 PM EDT - Market closed
Editas Medicine Employees
Editas Medicine had 246 employees as of December 31, 2024. The number of employees decreased by 19 or -7.17% compared to the previous year.
Employees
246
Change (1Y)
-19
Growth (1Y)
-7.17%
Revenue / Employee
$158,134
Profits / Employee
-$962,841
Market Cap
270.66M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 246 | -19 | -7.17% |
| Dec 31, 2023 | 265 | 39 | 17.26% |
| Dec 31, 2022 | 226 | -38 | -14.39% |
| Dec 31, 2021 | 264 | 29 | 12.34% |
| Dec 31, 2020 | 235 | 27 | 12.98% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
EDIT News
- 16 days ago - Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm? - Seeking Alpha
- 21 days ago - Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress - GlobeNewsWire
- 24 days ago - Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Editas Medicine, Inc. - Special Call - Seeking Alpha
- 2 months ago - Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate - GlobeNewsWire
- 2 months ago - Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate - GlobeNewsWire
- 2 months ago - Editas Medicine to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Editas Medicine Announces Second Quarter 2025 Results and Business Updates - GlobeNewsWire